Evidence map›Paper›PMID 40416368›Full record

ArticleFrontiers in nutrition2025

Effect of

Rui Wang, Guoming Zhang, Xiaoya Wang, Zefeng Xing, Zhen Li, Lixiang Li

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06077383 (Effect of Weizmania Coagulans BC99 Intervention on Gut Microbiota and Metabolic Markers in Overweight/Obese Adults), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06077383 nacompletednot on this map

Effect of Weizmania Coagulans BC99 Intervention on Gut Microbiota and Metabolic Markers in Overweight/Obese Adults: Randomized, Double-blind, Placebo-controlled Trial

TypeinterventionalSponsorQilu Hospital of Shandong UniversityRan2023 to 2024Enrolled72ConditionsOverweightArmsWeizmania Coagulans BC99
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Metabolites · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rui Wang *Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Guoming Zhang *Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Xiaoya WangDepartment of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Zefeng XingDepartment of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Zhen LiDepartment of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Lixiang LiDepartment of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Probiotic supplementation is a safe and effective way to reduce overweight and obesity by regulating the gut microbiota. The Methods: A total of 66 adult individuals were randomly assigned to a probiotic group (supplemented with 5 × 10 Results: After 8 weeks of oral administration, BC99 intervention significantly decreased the body weight of overweight individual ( Discussion: These findings suggest that Clinical trial registration: ClinicalTrials.gov, identifier NCT06077383.

Indexed as

B. coagulansgut microbiotaobeseoverweightprobiotics

Identifiers

PMID40416368
PMCPMC12100662

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.